How to Organize Technical Files for Medical Device Registration in Vietnam?

To organize technical files for medical device registration in Vietnam, companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base. They should then assess technical files, quality system, labeling and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Vietnam registration typically affects technical files, authorized representative, importer cooperation, labeling language, quality system certification, and subsequent change maintenance. If the process is driven only by "what documents to submit," it is easy to encounter deficiencies or rework in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends that companies incorporate this issue into a unified strategy for GHWP member states and multi-country market access, using a reusable core technical file to support localization in different markets, rather than recreating documentation for each country on an ad hoc basis.

This content is compiled based on AIMEILI's regulatory practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Publication date: 2026-07-10 16:32 | Update date: 2026-07-10 16:32

This article addresses common questions that companies need to prioritize in practical projects regarding international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documents and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI's View
• Frequently Asked Questions
• Continue Reading
• Scope of Application

Applicable Scenarios and Core Questions

Companies searching for "how to organize technical files for medical device registration in Vietnam" typically want to solve not a conceptual explanation but a practical judgment: whether existing documentation can support a Vietnam submission, whether a local agent or authorized representative is needed, why timelines get extended, and which issues affect launch plans. This question often involves product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first create reusable versions of core technical files, quality system certificates, performance verification, clinical evidence, and labeling, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is powered, and whether it contains software or has IVD attributes, and then determine the risk classification and submission pathway. Once the pathway is incorrect, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For a Vietnam project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are vaguely addressed only in commercial contracts, they can easily affect market control later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, labeling warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on how many documents the company uploads.

Common Mistakes

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating and submitting domestic NMPA documents without rearranging evidence according to the Vietnam pathway.
• Too many model specifications, but insufficient coverage in test reports, clinical evidence, or labeling.
• Selecting a local agent solely based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistencies among labeling, instructions for use, promotional materials, and registration claims, leading to deficiencies or post-market compliance risks.
• Failure to plan for multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base and avoid discovering critical evidence gaps after submission.

• Compile a target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table, specifying items that require additional testing, translation, notarization, or supplementary declarations.

AIMEILI's View

AIMEILI recommends that companies not view Vietnam registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the evidence chain; third, regulatory responsibility boundaries of local partners. If these three are unclear, even if the documentation appears extensive, the project may still experience repeated deficiencies, agent communication issues, and post-market maintenance problems.

Frequently Asked Questions

Can domestic documents be used directly for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labeling adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage product lists, model specifications, registration pathways, document owners, translation status, testing status, local agent communication records, and expected submission times in one table. This allows for timely identification of documentation gaps and helps management determine whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country-specific requirements. In particular, labeling, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically check whether the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model specifications, instructions for use version, and test reports are inconsistent, even if the company has prepared a large number of documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Vietnam registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transportation conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, labeling versions, and regulatory update records. Many companies invest significant effort in obtaining the certificate but neglect post-market maintenance. Subsequently, when production address changes, model expansion, instructions for use updates, or agent changes occur, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first determine target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly to help companies develop replicable overseas compliance capabilities and reduce the cost of starting from scratch each time they enter a new market.

Continue Reading

Previous: How to Determine Product Classification for Medical Device Registration in Vietnam?

Next: How to Localize Labeling and Instructions for Use for Medical Device Registration in Vietnam?

Recommended Reading:

• How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• How to Determine Product Classification for Medical Device Registration in Malaysia?
• How to Organize Technical Files for Medical Device Registration in Malaysia?
• How to Localize Labeling and Instructions for Use for Medical Device Registration in Malaysia?
• How to Prepare Clinical Evaluation Documents for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Scope of Application

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as supplementary judgment.

Scope of Application: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.